Response and resistance to BET bromodomain inhibitors in triple-negative breast cancerShaokun Shu, Kornélia Polyák, Doris P. Tabassum et al.|Nature|2016Cited by 629
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancerDaniel G. Stover, Nancy U. Lin, Carlos R. Gil Del Alcazar et al.|npj Breast Cancer|2018Cited by 150